F. Hoffmann-La Roche AG


About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Roche retains sole responsibility for content © 2018 F. Hoffmann-La Roche AG. All trademarks used or mentioned in this release are protected by law.

1 December 2017 - 30 November 2018

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for F. Hoffmann-La Roche AG published between 1 December 2017 - 30 November 2018 which are tracked by the Nature Index.

Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

129 53.68

Outputs by subject (FC)

Subject AC FC
Chemistry 27 13.11
Life Sciences 107 42.26
Physical Sciences 2 0.04

Highlight of the month

A new inhalable drug for asthma

© Karl Tapales/Getty

© Karl Tapales/Getty

An inhalable version of immune-suppressing drugs called JAK inhibitors helped improve symptoms of asthma in mouse and guinea pig models of the disease.

JAK inhibitors are already approved in pill form for treating rheumatoid arthritis, ulcerative colitis and other autoimmune disorders. In mouse models of asthma, these drugs have previously shown some therapeutic potential, but side effects precluded their further development for treating asthma in people.

Now, researchers at the Roche subsidiary Genentech have created a JAK inhibitor that can be administered as a dry powder through inhalation. This delivery system ensures that the drug stays in the lungs, with minimal systemic exposure to the rest of the body.

In the animal models, the drug reduced lung inflammation, improved allergen-induced airway hypersensitivity and exhibited better asthma control than standard corticosteroid therapy, with minimal toxicity.

The researchers conclude that human trials are now warranted.

Supported content

  1. Science Translational Medicine 10, eaao2151 (2018). doi: 10.1126/scitranslmed.aao2151

View the article on the Nature Index

See more research highlights from F. Hoffmann-La Roche AG

More research highlights from F. Hoffmann-La Roche AG

1 December 2017 - 30 November 2018

International vs. domestic collaboration by FC

  • 8.96% Domestic
  • 91.04% International

Note: Hover over the graph to view the percentage of collaboration.

Note: Collaboration is determined by the fractional count (FC), which is listed in parentheses.

Affiliated joint institutions and consortia

Return to institution outputs